Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 황은숙 | * |
dc.date.accessioned | 2016-08-28T12:08:09Z | - |
dc.date.available | 2016-08-28T12:08:09Z | - |
dc.date.issued | 2012 | * |
dc.identifier.issn | 0731-7085 | * |
dc.identifier.other | OAK-8625 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/222508 | - |
dc.description.abstract | TM-25659 compound, a novel TAZ modulator, is developed for the control of bone loss and obesity. TAZ is known to bind to a variety of transcription factors to control cell differentiation and organ development. A selective and sensitive method was developed for the determination of TM-25659 concentrations in rat plasma. The drug was measured by liquid chromatography-tandem mass spectrometry after liquid-liquid extraction with ethyl acetate. TM-25659 and the internal standard imipramine were separated on a Hypersil GOLD C18 column with a mixture of acetonitrile-ammonium formate (10. mM) (90:10, v/v) as the mobile phase. The ions m/z 501.2 → 207.2 for TM-25659 and m/z 281.0 → 86.0 for imipramine in multiple reaction monitoring mode were used for the quantitation. The calibration range was 0.1-100μg/ml with a correlation coefficient greater than 0.99. The lower limit of quantitation of TM-25659 in rat plasma was 0.1μg/ml. The percent recoveries of TM-25659 and imipramine were 98.6% and 95.7% from rat plasma, respectively. The intra- and inter-batch precisions were 3.17-15.95% and the relative error was 0.38-10.82%. The developed assay was successfully applied to a pharmacokinetic study of TM-25659 administered intravenously (10. mg/kg) to rats. © 2012 Elsevier B.V.. | * |
dc.language | English | * |
dc.title | Determination of a novel TAZ modulator, 2-butyl-5-methyl-6-(pyridine-3-yl)-3-[2'-(1H-tetrazole-5-yl)-biphenyl-4-ylmethyl]-3H imidazo[4,5-b]pyridine] (TM-25659) in rat plasma by liquid chromatography-tandem mass spectrometry | * |
dc.type | Article | * |
dc.relation.volume | 63 | * |
dc.relation.index | SCI | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 47 | * |
dc.relation.lastpage | 52 | * |
dc.relation.journaltitle | Journal of Pharmaceutical and Biomedical Analysis | * |
dc.identifier.doi | 10.1016/j.jpba.2012.01.036 | * |
dc.identifier.wosid | WOS:000302208500007 | * |
dc.identifier.scopusid | 2-s2.0-84862801661 | * |
dc.author.google | Choi S.H. | * |
dc.author.google | Lee K.-R. | * |
dc.author.google | Woo J.-C. | * |
dc.author.google | Kim N.J. | * |
dc.author.google | Moon D.C. | * |
dc.author.google | Hwang E.S. | * |
dc.author.google | Ahn S.-H. | * |
dc.author.google | Bae M.A. | * |
dc.author.google | Kim M.-S. | * |
dc.contributor.scopusid | 황은숙(8688011100) | * |
dc.date.modifydate | 20240123102458 | * |